MiMedx Group, Inc $MDXG Shares Acquired by State of Wyoming

State of Wyoming lifted its position in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 347.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 324,492 shares of the company’s stock after buying an additional 251,932 shares during the quarter. State of Wyoming’s holdings in MiMedx Group were worth $1,512,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in MiMedx Group during the second quarter worth approximately $46,795,000. Nantahala Capital Management LLC acquired a new position in MiMedx Group in the 2nd quarter valued at $18,355,075. Paradigm Capital Management Inc. NY acquired a new position in MiMedx Group in the 2nd quarter valued at $15,681,000. Renaissance Technologies LLC raised its holdings in MiMedx Group by 22.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after acquiring an additional 552,806 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of MiMedx Group by 8.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,694,002 shares of the company’s stock worth $10,640,000 after purchasing an additional 214,633 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Stock Performance

MiMedx Group stock opened at $3.88 on Friday. MiMedx Group, Inc has a 1 year low of $3.03 and a 1 year high of $7.97. The firm has a 50 day moving average price of $4.49 and a 200 day moving average price of $4.29. The company has a market cap of $565.55 million, a price-to-earnings ratio of -29.85 and a beta of 1.18.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, October 28th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $62.28 million for the quarter, compared to analysts’ expectations of $68.56 million. MiMedx Group had a positive return on equity of 2.39% and a negative net margin of 6.32%. Sell-side analysts predict that MiMedx Group, Inc will post -0.10 EPS for the current year.

Wall Street Analyst Weigh In

MDXG has been the topic of several analyst reports. Wall Street Zen upgraded MiMedx Group from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Raymond James Financial set a $8.00 price objective on MiMedx Group in a research report on Monday, August 17th. Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday. Seaport Research Partners downgraded MiMedx Group to a “neutral” rating in a research report on Monday, August 17th. Finally, Mizuho set a $7.00 target price on MiMedx Group in a research report on Thursday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.14.

About MiMedx Group

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.